On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
Desai is currently serving the company as Group Finance Controller
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Subscribe To Our Newsletter & Stay Updated
